ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Early Experience Using Donor-Derived Cell-Free DNA for Detection of Rejection in Kidney Transplantation

E. Huang, A. Vo, J. Choi, A. Peng, S. Sethi, R. Najjar, S. Jordan.

Medicine/Nephrology, Cedars Sinai Medical Center, Los Angeles, CA.

Meeting: 2018 American Transplant Congress

Abstract number: A110

Keywords: Kidney transplantation, Rejection

Session Information

Session Name: Poster Session A: Kidney Acute Antibody Mediated Rejection

Session Type: Poster Session

Date: Saturday, June 2, 2018

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall 4EF

Introduction:

Donor-derived cell free DNA (ddDNA; Allosure, CareDX) has been validated as a non-invasive test that can discriminate rejection from non-rejection in kidney transplantation, but has not been externally validated. We describe our early experience using ddDNA and report performance characteristics of ddDNA for discrimination of rejection.

Methods:

We measured ddDNA on 25 kidney transplant recipients, 12 of whom underwent confirmatory allograft biopsy. Receiver operating characteristic curves (ROC) were generated for any rejection (AR; antibody- or cell-mediated, CMR) and antibody-mediated rejection (ABMR) alone. The area under the ROC curve (AUC) and associated positive (PPV) and negative predictive values (NPV) were calculated.

Results:

Blood for ddDNA was taken at a median 1125 days post-transplant (IQR: 338, 2844). The median GFR was 48.2 ml/min/1.73 m2 (IQR: 40.2-65.8). Donor-specific antibodies were present in 11/25 (44%). The median ddDNA was 1.0% (IQR: 0.3-1.5). Twelve patients had ddDNA below or near the lower limit of detection (≤0.29%); two were biopsied and did not have rejection (ddDNA: undetectable and 0.28%). Twelve patients underwent biopsy (median ddDNA 1.7%, IQR: 1.3-2.5), of whom 7 had ABMR and 1 had CMR. Two with ddDNA≥1.0% had no rejection on biopsy (ddDNA 1.2%: negative; ddDNA 1.5%: C3 glomerulopathy). Discrimination for AR (AUC 93.8%, 95% CI: 79.1-100%) and ABMR (AUC 95.7%, 95% CI: 85.6-100%) was high (fig 1). A ddDNA threshold ≥1.0% for AR yielded a PPV of 80.0% and NPV 100%; increasing the threshold to ≥1.4% improved the PPV to 88.9% while maintaining NPV 100%. For ABMR, the optimal ddDNA threshold was ≥1.9% (PPV: 100%; NPV: 83.3%).

Conclusions:

Test performance of ddDNA was similar to previously reported internal validation data. Although the number assessed was small, our preliminary experience reinforces that ddDNA may be useful for discrimination of AR and ABMR from non-rejection states. Detection of high ddDNA in a patient with C3 glomerulopathy argues for further studies to evaluate the impact of glomerulonephritis on ddDNA test performance.

CITATION INFORMATION: Huang E., Vo A., Choi J., Peng A., Sethi S., Najjar R., Jordan S. Early Experience Using Donor-Derived Cell-Free DNA for Detection of Rejection in Kidney Transplantation Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Huang E, Vo A, Choi J, Peng A, Sethi S, Najjar R, Jordan S. Early Experience Using Donor-Derived Cell-Free DNA for Detection of Rejection in Kidney Transplantation [abstract]. https://atcmeetingabstracts.com/abstract/early-experience-using-donor-derived-cell-free-dna-for-detection-of-rejection-in-kidney-transplantation/. Accessed June 3, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences